Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.

Front Oncol · 2020 · PMC7308557 · PMID 32612955

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

marginally insignificantno p-value reported

Although the OS benefit from PARP inhibitors was limited, the results should be interpreted with caution, considering that they had a favorable trend and were only marginally insignificant at a 95% CI level.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.